According to Almac, the partnership enables both companies to provide clients and sites with “streamlined access” to clinical trial Interactive Response Technology (IRT) solutions, including Almac’s IXRS® technology.
As part of the arrangement, several inVentiv’s IRT specialists will also join Almac’s consultancy team.
Matthew Cocking, Director of Marketing at Almac Clinical Technologies, told us the rationale for both organizations was simple: “to provide biopharmacuetical clients with best-in-class products and services via the most effective delivery mechanism possible.”
Cocking explained inVentiv chose to pursue the development of a strategic partnership after recognizing Almac’s dedication to continued innovation in the IRT space.
“This transition will enable inVentiv Health to capitalize on Almac’s technical capabilities of applying best practices to random facilitation of drug trial enrollment and medication management while continuing to provide this service seamlessly to inVentiv’s clients with even greater capacity,” he added.
Gregory Skalicky, Chief Commercial Officer, inVentiv Health Clinical Division commented in the press release:
“We’re committed to accelerating clinical trials and see tremendous value in applying leading technology solutions to streamline the process. This partnership will enable inVentiv Health to enhance its clinical services continuum by offering clients access to Almac’s comprehensive, best-in-class IRT services to unlock further efficiencies in trial study configuration and deployment.”
inVentiv is not providing any additional comment at this time.